ResearchMoz

Global Wireless Infrastructure Market 2011-2015

Technavio
Published Date » 2012-05-07
No. Of Pages » 34
   
   
TechNavios analysts forecast the Global Wireless Infrastructure market to grow at a CAGR of 1.9 percent over the period 20112015. One of the key factors contributing to this market growth is the rapid deployment of LTE networks by telecom operators. The Global Wireless Infrastructure market has also been witnessing development of energy-efficient equipment. However, market cannibalization of technologies could pose a challenge to the growth of this market.   TechNavios report, the Global Wireless Infrastructure Market 20112015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Wireless Infrastructure market landscape and its growth prospects...
Table Of Contents

1. Executive Summary

2. Introduction

3. Market Coverage

4. Market Landscape

5. Geographical Segmentation

6. Vendor Landscape

7. Market Growth Drivers

8. Drivers and their Impact

9. Market Challenges

10. Impact of Drivers and Challenges

11. Market Trends

12. Key Vendor Analysis
12.1 Ericsson Inc.
12.2 Nokia Siemens Networks Ltd.
12.3 Huawei Technologies Co. Ltd.
12.4 Alcatel-Lucent Inc.

13. Other Reports in this Series

List of Exhibits
:

Exhibit 1: Global Wireless Infrastructure Market 20112015 (US$ billion)
Exhibit 2: Global Wireless Infrastructure Market Segmentation by Technology
Exhibit 3: Global Wireless Infrastructure Market By Segments 20112015 (US$ billion)
Exhibit 4: Global Wireless Infrastructure Market by Geographical Segmentation 2011
Exhibit 5: Global Wireless Infrastructure Market by Vendor Segmentation 2011

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Non Small Cell Lung Cancer Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Globally, the Non-Small-Cell Lung Cancer (NSCLC) drug market will increase from USD 4.3 billion in 2009 to USD 6.9 billion in 2019 and the market is growing with a CAGR of 4.84% during 2009 to 2019. The major markets in these segments are the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The global top five global brands in NSCLC with the largest market share are Avastin, Tarceva, Alimta, Gemzar and Taxotere. For growth in the future there are drugs in the pipeline and in clinical trials at the phase 3 process development in the non small cell lung...
Immunoglobulin Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Immunoglobulin’s also called as antibodies are large Y-shaped protein produced by B-cell.  These are the glycoprotein molecule produced by plasma cells in response to entry of foreign entity such as bacteria and viruses in the body. Production of antibodies is an important function of immune system. Antibodies use binding mechanism for neutralizing the activity of a foreign particle called as an antigen. These are made up of basic structural unit’s namely heavy chains and light chains.  In mammals five different types of antibodies (IgA, IgD, IgE, IgG and...
Polyphenylene Sulfide Market - Global Industry Analysis, Size, Share, Trends And Forecast 2013 - 2019
By - Transparency Market Research
Polyphenylene sulfide is a polymer that is organic in nature and mainly consists of the aromatic rings which are linked with sulfides. The synthetic fibers manufactured from polyphenylene sulfide are known to offer high resistance to the thermal and chemical attacks. Polyphenylene sulfide is a crystallized thermoplastic polymer that exhibits characteristics such as excellent chemical resistance, high heat deflection temperature, flame retardance and outstanding dimensional stability. Polyphenylene sulfide is also known for its continuous service temperature which mainly ranges from 1800C...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...